1456906-91-4

Upstream product

• 1456905-59-1 2-(N-benzenecarbonylamino)-6-(O-methanesulfonyl)-N-benzylhexanamide 
• 76-05-1 trifluoroacetic acid 
• 100-46-9 benzylamine 
• 1456905-57-9 (S)-N-(1-(benzylamino)-6-hydroxy-1-oxohexan-2-yl)benzamide 
• 1456905-55-7 6-amino-2-(benzenecarbonyl)amino-N-(benzyl)hexanamide 
• 1456905-53-5 2-(N-benzenecarbonylamino)-6-(N-benzyloxycarbonylamino)-N-benzylhexanamide 
• 118865-76-2 2-amino-N-benzyl-6-{(benzyloxycarbonyl)amino}hexanamide hydrochloride 
• 123441-84-9 6-(N-benzyloxycarbonyl)amino-2-(N-tert-butoxycarbonylamino)-N-benzylhexanamide 
• 155-09-9 trans-2-phenylcyclopropylamine 
• 2389-45-9 Boc-Lys(Z)-OH 

Relevant academic research and scientific papers

LSD1-SELECTIVE INHIBITOR HAVING LYSINE STRUCTURE

A primary object of the present invention is to provide a novel compound having LSD1-selective inhibitory activity and having an antitumor/anticancer action, an antiviral action, and the like. As means for achieving such object, provided is a compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof: [in the formula, R1 to R5, A, and *1 to *3 are as defined in Description].

Lysine-specific demethylase 1-selective inactivators: Protein-targeted drug delivery mechanism

Drug drop off: Given that lysine-specific demethylase 1 (LSD1) could be potently and selectively inactivated by delivering phenylcyclopropylamine (PCPA), a weak and nonselective LSD1 inhibitor, directly to the enzyme's active site, a novel series of LSD1 inactivators (1) were designed. Biological and mechanistic studies indicate that 1 inhibits LSD1 potently and selectively. Copyright